Collaboration and competition: ethics in toxicology

What are our attitudes to research resourcing, publication and the peer review system?  The British Toxicology Society (BTS) is conducting a survey to establish attitudes of toxicologists to key questions such as ‘I believe collaboration to be important in driving toxicology research in the UK’ and ‘I believe the current system of peer review for [...]

By |2018-09-27T18:18:55+00:00September 27th, 2018|Toxicology|Comments Off on Collaboration and competition: ethics in toxicology

Choosing the right non-clinical CRO

Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical and scientific skills. In selecting a CRO, the sponsor typically [...]

By |2018-09-12T14:07:14+00:00September 19th, 2018|Toxicology, Press|Comments Off on Choosing the right non-clinical CRO

Paul Duffy Presents at EUROTOX 2018

Dr Paul Duffy will be speaking at EUROTOX this September. On Monday 3rd of September at 16:30 in the SILVER Hall Paul will address “Old drugs in new guises: the toxicology of repurposing” chaired and introduced by Ruth Roberts and Dr Miranda Cornet from UCB in Belgium.  Paul will present case studies to illustrate the [...]

By |2018-08-23T12:05:58+00:00August 22nd, 2018|Toxicology, Events|Comments Off on Paul Duffy Presents at EUROTOX 2018

ApconiX at EUROTOX 2018

Dr Michael Morton, Professor Ruth Roberts, Dr Richard Knight and Dr Paul Duffy will be attending EUROTOX this September in Brussels. The theme for 2018 is “Toxicology Out of the Box” and reflects the federation’s willingness and enthusiasm to offer an innovative, forward-looking and imaginative scientific programme.  ‘"The theme for EUROTOX aligns perfectly with our [...]

By |2018-08-15T09:24:31+00:00August 15th, 2018|Toxicology, Events|Comments Off on ApconiX at EUROTOX 2018

Mother and Daughter on Front cover

Ruth Roberts and Emma Walker were featured on the front cover of Toxicology Research this month.  The mother and daughter’s review article, Collaboration and competition: ethics in toxicology hit the headlines in Volume 7. The front cover was painted by Emma, an accomplished artist as well as scientist.  Emma is currently studying for her Master’s [...]

By |2018-07-22T18:28:03+00:00July 22nd, 2018|Toxicology, Publications|Comments Off on Mother and Daughter on Front cover

Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients. Dr Richard Knight of Alderley Park-based ApconiX told last month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to [...]

By |2018-07-11T10:12:48+00:00March 27th, 2018|Toxicology|Comments Off on Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Abstract: Neurotoxicity has been linked with exposure to a number of common drugs and chemicals, yet efficient, accurate, and minimally invasive methods to detect it are lacking. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid have great potential due to the relative ease of sampling but at present, data on [...]

By |2018-06-27T16:11:13+00:00February 28th, 2018|Toxicology, Publications|Comments Off on Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Redx Pharma Announces First Patient Dosed in Phase 1/2a

Redx Pharma has commenced a Phase I study for a novel cancer treatment at The Christie in Manchester. The compound, RXC004, is a novel, oral, potent small molecule Porcupine inhibitor, and targets the Wnt pathway that is implicated in the maintenance of cancer stem cells. ApconiX were proud to work with our Redx colleagues in [...]

By |2018-07-11T12:18:33+00:00February 13th, 2018|Toxicology|Comments Off on Redx Pharma Announces First Patient Dosed in Phase 1/2a

Magic Mushrooms May Treat Depression

This recent article in the Sunday Times discusses how an extract of magic mushrooms may be able to make significant improvements in the treatment of severe depression. We were delighted to bring ApconiX's drug project toxicologist expertise to the team of experts working with COMPASS Pathways to find a safe, efficient and effective route into [...]

By |2018-05-30T15:54:28+00:00February 13th, 2018|Toxicology|Comments Off on Magic Mushrooms May Treat Depression

Collaboration and Competition: Ethics in Toxicology

Two of the biggest ethical challenges in pharmaceutical toxicology are the use of animals in testing and the high safety-related attrition rates in new drug development.  Yet very little is invested in these two fields compared with investment in new efficacy models, new disease targets and new technologies.  How can this be addressed?  In this [...]

By |2018-05-30T16:00:00+00:00February 9th, 2018|Toxicology, Publications|Comments Off on Collaboration and Competition: Ethics in Toxicology